BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Cuts Target Price to $78
Citi Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $95
Apogee Therapeutics Analyst Ratings
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments
Jefferies Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $86
Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $116
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $80
Apogee Therapeutics Analyst Ratings
Stifel Maintains Apogee Therapeutics(APGE.US) With Buy Rating
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
Apogee Therapeutics Analyst Ratings
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Promising Potential of Apogee Therapeutics: A Buy Rating Backed by Innovative Pipeline and Strategic Approach
TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Price Target Raised to $110.00/Share From $95.00 by Guggenheim
Apogee Therapeutics Analyst Ratings